文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

成人铜绿假单胞菌呼吸机相关肺炎抗生素疗程8天与15天的比较:一项随机、对照、开放标签试验

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial.
PubMed 文献 · Intensive Care Med · 2022-05-13
一句话结论在铜绿假单胞菌呼吸机相关肺炎(PA-VAP)中,8天短疗程相比15天长疗程未能证明非劣效,短疗程可能伴随PA-VAP复发增加,但研究把握度不足限制解读。

这项全国性、随机、开放标签、多中心非劣效试验纳入成人PA-VAP患者,1:1随机接受8天或15天抗生素治疗,预设复合终点为ICU住院期间及90天内死亡与PA-VAP复发的复合终点。研究因入组缓慢在24个月后停止。意向治疗人群(n=186)中,15天组复合终点25.5%(25/98),8天组35.2%(31/88),差值9.7%(90%CI -1.9%~21.2%)。ICU期间PA-VAP复发率15天组9.2%,8天组17%。两组机械通气中位天数、ICU住院中位天数、肺外感染数和多重耐药(MDR)病原体获得情况相似。作者结论为未能证明短疗程非劣效,短疗程策略可能伴随PA-VAP复发增加,但缺乏把握度限制了解读。

要点

  • 在成人PA-VAP意向治疗人群(n=186)中,15天组复合终点(死亡+PA-VAP复发)25.5%(25/98),8天组35.2%(31/88),差值9.7%(90%CI -1.9%~21.2%),未能证明8天非劣效于15天。
  • ICU期间PA-VAP复发率15天组为9.2%,8天组为17%。
  • 两组机械通气中位天数、ICU住院中位天数、肺外感染数和ICU期间MDR病原体获得情况相似。
  • 研究因入组缓慢在24个月后停止,作者指出缺乏把握度限制了对本研究的解读。
  • 作者结论:短疗程策略可能伴随PA-VAP复发增加,但该研究未能证明短疗程非劣效。

适用人群与场景

  • 纳入:诊断为铜绿假单胞菌呼吸机相关肺炎(PA-VAP)的成人患者。
  • 场景:全国性、多中心、随机、开放标签、非劣效试验,终点评估在ICU住院期间及90天内。

处置流程与药物剂量

  • 随机1:1分配接受短疗程抗生素治疗(8天)或长疗程抗生素治疗(15天)。

研究设计与关键结果

  • 研究设计:全国性、随机、开放标签、多中心、非劣效试验;因入组缓慢在24个月后停止。
  • 意向治疗人群n=186;复合终点(ICU住院期间及90天内死亡与PA-VAP复发)15天组25.5%(25/98)vs 8天组35.2%(31/88),差值9.7%(90%CI -1.9%~21.2%)。
  • ICU期间PA-VAP复发率:15天组9.2% vs 8天组17%。
  • 两组机械通气中位天数、ICU住院中位天数、肺外感染数和ICU期间MDR病原体获得情况相似。

证据类型、等级与局限

  • 证据类型:随机、对照、开放标签、多中心、非劣效试验。
  • 局限:研究因入组缓慢在24个月后停止;作者指出缺乏把握度限制了对本研究的解读。

对床旁实践的改变

  • 作者结论:本研究未能证明短疗程(8天)抗生素治疗PA-VAP非劣效于长疗程(15天)。
  • 作者认为:短疗程策略可能伴随PA-VAP复发增加。
  • 作者指出:缺乏把握度限制了对本研究的解读。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Duration of antibiotic therapy for ventilator-associated pneumonia (VAP) due to non-fermenting Gram-negative bacilli (NF-GNB), including Pseudomonas aeruginosa (PA) remains uncertain. We aimed to assess the non-inferiority of a short duration of antibiotics (8 days) vs. prolonged antibiotic therapy (15 days) in VAP due to PA (PA-VAP).

METHODS: We conducted a nationwide, randomized, open-labeled, multicenter, non-inferiority trial to evaluate optimal duration of antibiotic treatment in PA-VAP. Eligible patients were adults with diagnosis of PA-VAP and randomly assigned in 1:1 ratio to receive a short-duration treatment (8 days) or a long-duration treatment (15 days). A pre-specified analysis was used to assess a composite endpoint combining mortality and PA-VAP recurrence rate during hospitalization in the intensive care unit (ICU) within 90 days.

RESULTS: The study was stopped after 24 months due to slow inclusion rate. In intention-to-treat population (n = 186), the percentage of patients who reached the composite endpoint was 25.5% (N = 25/98) in the 15-day group versus 35.2% (N = 31/88) in the 8-day group (difference 9.7%, 90% confidence interval (CI) -1.9%-21.2%). The percentage of recurrence of PA-VAP during the ICU stay was 9.2% in the 15-day group versus 17% in the 8-day group. The two groups had similar median days of mechanical ventilation, of ICU stay, number of extra pulmonary infections and acquisition of multidrug-resistant (MDR) pathogens during ICU stay.

CONCLUSIONS: Our study failed to show the non-inferiority of a short duration of antibiotics in the treatment of PA-VAP, compared to a long duration. The short duration strategy may be associated to an increase of PA-VAP recurrence. However, the lack of power limits the interpretation of this study.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bouglé A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med. 2022. PMID: 35552788. doi:10.1007/s00134-022-06690-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。